NOVEL SARS-CoV-2 POINT-OF-CARE DIAGNOSTIC TEST
CTS Viral Antigen Detection Test to Detect the Status of Current Infection
Simpler, more effective, more accessible and more cost-efficient DIAGNOSTICS
Our viral antigen detection test has been developed at Harvard University to provide a novel POC diagnostic test using microfluidic based-technology to deliver easy-to-use, accurate and fast diagnostic results. We look forward to working with governments, health system clinics, pharmacies, health care centers in both Canada and US to address the COVID-19 crisis in a way that is affordable, reliable and accessible to everyone.
With fast and accurate results in a few minutes, our SARS-CoV-2 viral antigen detection test will give infected patients the information they need to get care quickly and limit the amount of time they unknowingly spread the virus to others. We are also developing our new technology to use saliva as a promising sample for facilitating testing due to the ease, safety, and non-invasive nature of its collection.
CTS mobile application:
This novel POC diagnostic test which pairs with a user-friendly mobile app, allows people who test negative to get a temporary digital health pass and people who test positive to get tracked to prevent spreading the virus and follow-up their treatment at the right time and right settings.is
This integration enables the physician to verify infection quickly, begin proper treatment and initiate isolation precautions helping prevent further spread of infections. It also enables institutions to derive data insights to monitor patients’ infection status in real-time as well as providing very useful information for decision makers to change the policies regarding controlling the spread of virus during the second wave of pandemic.